{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T20:30:15Z","timestamp":1782678615145,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyloidosis is increasingly recognized as a contributor to heart failure, particularly among older adults and patients with heart failure with preserved ejection fraction (HFpEF). Despite advances in diagnostic imaging and disease-modifying therapies, amyloidosis remains underdiagnosed in many settings, and population-level data examining its co-occurrence with cardiovascular disease on death certificates are limited. This study examined two decades of national mortality data to evaluate deaths co-coded with amyloidosis and cardiovascular disease (CVD) in the United States and to assess temporal trends and demographic disparities in age-adjusted mortality rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted using mortality data from the CDC WONDER database spanning 1999\u20132020. Age-adjusted mortality rates (AAMRs) per 1,000,000 persons were calculated, and trends were assessed using Average Annual Percentage Change (AAPC) and Annual Percent Change (APC) using Joinpoint 5.0.2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 1999 and 2020, 26,391 amyloidosis and CVD-related deaths occurred among adults aged 25 years and older in the United States. The overall AAMR for deaths co-coded with amyloidosis and CVD increased from 4.40 in 1999 to 9.31 in 2020, with an AAPC of 3.49 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The most pronounced increase occurred between 2018 and 2020 (APC: 13.60). Rates were higher among men than women, with both sexes showing a marked increase in the last decade. African American or Black individuals had the highest rates (11.40), followed by White (5.11) and Hispanic (3.86) individuals. Rates were highest in the Northeast region (6.71). Metropolitan areas had higher rates than non-metropolitan areas (5.73 vs. 4.76), with a more pronounced increase in metropolitan regions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Age-adjusted mortality rates for deaths co-coded with amyloidosis and cardiovascular disease have increased over time, likely reflecting improved recognition and documentation. Higher rates of co-coded deaths were noted among men, African Americans, and individuals in the Northeast region, highlighting potential disparities in diagnostic access and recognition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05510-8","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:16:03Z","timestamp":1769778963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends and disparities in amyloidosis and cardiovascular disease mortality: a population-based retrospective study in the United States (1999\u20132020)"],"prefix":"10.1186","volume":"26","author":[{"given":"Faizan","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehmasp Rehman","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris Bin","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenilkumar","family":"Kotadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider Hussain","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Qadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najam","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"Suppl 1","key":"5510_CR1","first-page":"39","volume":"8","author":"VK Ton","year":"2015","unstructured":"Ton VK, Mukherjee M, Judge DP. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clin Med Insights Cardiol. 2015;8(Suppl 1):39\u201344. PMID: 25628512; PMCID: PMC4284988.","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"5510_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/hearts6010004","volume":"6","author":"Z Bashir","year":"2025","unstructured":"Bashir Z, Khan B, Bukhari S. Cutting-Edge diagnostic tools for cardiac amyloidosis detection. Hearts. 2025;6(1):4. https:\/\/doi.org\/10.3390\/hearts6010004.","journal-title":"Hearts"},{"key":"5510_CR3","doi-asserted-by":"publisher","unstructured":"Oda S, Kidoh M, Nagayama Y, Takashio S, Usuku H, Ueda M, Yamashita T, Ando Y, Tsujita K, Yamashita Y. Trends in diagnostic imaging of cardiac amyloidosis: emerging knowledge and Concepts. Radiographics. 2020 Jul-Aug;40(4):961\u201381. https:\/\/doi.org\/10.1148\/rg.2020190069. Epub 2020 May 22. PMID: 32442047.","DOI":"10.1148\/rg.2020190069"},{"key":"5510_CR4","doi-asserted-by":"crossref","unstructured":"Bampatsias D, Wardhere A, Maurer MS. Treatment of transthyretin cardiac amyloidosis. Curr Opin Cardiol. 2024;39(5):407\u2013416. doi: 10.1097\/HCO.0000000000001156. Epub 2024 Apr 19. PMID: 38652263; PMCID: PMC11305969.","DOI":"10.1097\/HCO.0000000000001156"},{"issue":"10","key":"5510_CR5","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.3390\/jcm14103481","volume":"14","author":"L De Michieli","year":"2025","unstructured":"De Michieli L, Lupi A, Sinigiani G, Tietto A, Salvalaggio A, Branca A, Da Pozzo S, Rizzo S, Cecchin D, Perazzolo Marra M, Berno T, Corrado D, Briani C, Cipriani A. Pharmacological management of transthyretin amyloid cardiomyopathy: where we are and where we are going. J Clin Med. 2025;14(10):3481. https:\/\/doi.org\/10.3390\/jcm14103481. PMID: 40429476; PMCID: PMC12112366.","journal-title":"J Clin Med"},{"issue":"2","key":"5510_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113\u201322. PMID: 24720917; PMCID: PMC3984539.","journal-title":"JACC Heart Fail"},{"key":"5510_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.amjcard.2024.01.009","volume":"216","author":"R Khedraki","year":"2024","unstructured":"Khedraki R, Saef J, Martens P, Martyn T, Sul L, Hachamovitch R, Ives L, Estep JD, Tang WHW, Hanna M, Race. Genotype, and prognosis in black patients with transthyretin cardiac amyloidosis. Am J Cardiol. 2024;216:66\u201376. Epub 2024 Jan 25. PMID: 38278432.","journal-title":"Am J Cardiol"},{"key":"5510_CR8","unstructured":"Centers for Disease Control and Prevention., National Center for Health Statistics. Multiple Cause of Death 1999\u20132019 on CDC WONDER Online Database, Released in 2020. Data Are from the Multiple Cause of Death Files, 1999\u20132019, as Compiled from Data Provided by the 57 Vital Statistics Jurisdictions Through the Vital Statistics Cooperative Program, http:\/\/wonder.cdc.gov\/mcd-icd10.html"},{"key":"5510_CR9","unstructured":"Free, Published. 2019. https:\/\/www.icd10data.com\/ICD10CM\/Codes\/Changes\/New_Codes\/1?year=2019"},{"key":"5510_CR10","doi-asserted-by":"publisher","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. April 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"issue":"11","key":"5510_CR11","doi-asserted-by":"publisher","first-page":"102801","DOI":"10.1016\/j.cpcardiol.2024.102801","volume":"49","author":"F Ahmed","year":"2024","unstructured":"Ahmed F, Rojulpote C, Philip N, Maligireddy A, Mirza TR, Gonuguntla K, Lin CJ. Trends and disparities in cardiovascular deaths in systemic lupus erythematosus: a population-based retrospective study in the united States from 1999 to 2020. Curr Probl Cardiol. 2024;49(11):102801.","journal-title":"Curr Probl Cardiol"},{"key":"5510_CR12","first-page":"1","volume":"2","author":"DD Ingram","year":"2014","unstructured":"Ingram DD, Franco SJ. 2013 NCHS Urban-Rural classification scheme for counties. Vital Health Stat 2. 2014;2:1\u201373.","journal-title":"Vital Health Stat 2"},{"key":"5510_CR13","unstructured":"Program JR. Version 5.0.2 \u2013 May, Statistical methodology and applications Branch, surveillance research program. National Cancer Institute; 2023."},{"key":"5510_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jocs.15230","volume":"36","author":"RAB Visser","year":"2021","unstructured":"Visser RAB, Gravenor C, Ahmed S, Harky A. Amyloidosis and cardiovascular diseases: A clinical insight. J Card Surg. 2021;36:522\u20139. https:\/\/doi.org\/10.1111\/jocs.15230.","journal-title":"J Card Surg"},{"key":"5510_CR15","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1182\/blood-2024-212310","volume":"144","author":"UZ Asfeen","year":"2024","unstructured":"Asfeen UZ, Chakilam R, Parvez M, Avaiya NS, Chauhan S, Kotla NK, Kondaveety S, Igbenabor CA, Thappar KS, Desai R. Prevalence of major adverse cardiac and cerebrovascular events (MACCE) vs no Macce in elderly hospitalized patients with Amyloidosis; its gender and Racial disparities: A nationwide analysis (2016\u20132020). Blood. 2024;144:6902\u20136902. https:\/\/doi.org\/10.1182\/blood-2024-212310.","journal-title":"Blood"},{"key":"5510_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cardfail.2023.10.463","volume":"30","author":"K Sideris","year":"2024","unstructured":"Sideris K, Brinker L, Stinson L, Kyriakopoulos CP, Taleb J, Chang D, Waldron J, Kemeyou L, Florido R, Hanff T, et al. Health-Related quality of life as A predictor of heart failure admission and death in patients with amyloidosis. J Card Fail. 2024;30:310\u20131. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.463.","journal-title":"J Card Fail"},{"key":"5510_CR17","doi-asserted-by":"publisher","unstructured":"Gandhi K, Moras E, Isath A, Wu L, Correa A, Mahmood K. Incidence and predictors of sudden cardiac arrest in cardiac amyloidosis: A 5-Year retrospective analysis. Eur Heart J. 2023;44. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.618.","DOI":"10.1093\/eurheartj\/ehad655.618"},{"key":"5510_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/1570161116666180608121720","volume":"17","author":"M Kouvari","year":"2019","unstructured":"Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou E, Notara V, Tousoulis D, Pitsavos C. ATTICA & GREECS studies investigators Gender-Specific, Lifestyle-Related factors and 10-Year cardiovascular disease Risk; the ATTICA and GREECS cohort studies. Curr Vasc Pharmacol. 2019;17:401\u201310. https:\/\/doi.org\/10.2174\/1570161116666180608121720.","journal-title":"Curr Vasc Pharmacol"},{"key":"5510_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.7326\/M23-0507","volume":"176","author":"J He","year":"2023","unstructured":"He J, Bundy JD, Geng S, Tian L, He H, Li X, Ferdinand KC, Anderson AH, Dorans KS, Vasan RS, et al. Social, Behavioral, and metabolic risk factors and Racial disparities in cardiovascular disease mortality in U.S. Adults. Ann Intern Med. 2023;176:1200\u20138. https:\/\/doi.org\/10.7326\/M23-0507.","journal-title":"Ann Intern Med"},{"key":"5510_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCULATIONAHA.122.059174","volume":"146","author":"WS Post","year":"2022","unstructured":"Post WS, Watson KE, Hansen S, Folsom AR, Szklo M, Shea S, Barr RG, Burke G, Bertoni AG, Allen N, et al. Racial and ethnic differences in All-Cause and cardiovascular disease mortality: the MESA study. Circulation. 2022;146:229\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059174.","journal-title":"Circulation"},{"key":"5510_CR21","doi-asserted-by":"publisher","unstructured":"Aggarwal V, Mohanty A, Seltzer R, Ghannam H, Dev S. Abstract 12799: geographic variation in cardiac amyloidosis in U.S. Veterans from 2012 to 2021. Circulation. 2023;148. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.12799.","DOI":"10.1161\/circ.148.suppl_1.12799"},{"key":"5510_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","volume":"132","author":"D Bonderman","year":"2020","unstructured":"Bonderman D, P\u00f6lzl G, Ablasser K, Agis H, Aschauer S, Auer-Grumbach M, Binder C, D\u00f6rler J, Duca F, Ebner C, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132:742\u201361. https:\/\/doi.org\/10.1007\/s00508-020-01781-z.","journal-title":"Wien Klin Wochenschr"},{"key":"5510_CR23","doi-asserted-by":"publisher","unstructured":"Tan MC, Yeo YH, San BJ, Arsanjani R, Rosenthal J, Lee KS. Abstract 13020: trend and disparities in cardiovascular death in amyloidosis: A Population-Based retrospective study in the united States from 1999 to 2020. Circulation. 2023;148. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.13020.","DOI":"10.1161\/circ.148.suppl_1.13020"},{"key":"5510_CR24","doi-asserted-by":"publisher","unstructured":"Pham HN, Ramzi I, Alabagi A, Habib A, Aiti D, Barker K, Marco T, Mahmood N, Thien Ha LD, Tran VN, et al. Abstract 4145711: disparities related to amyloidosis and heart failure: A retrospective analysis of US mortality data. Circulation. 2024;150. https:\/\/doi.org\/10.1161\/circ.150.suppl_1.4145711.","DOI":"10.1161\/circ.150.suppl_1.4145711"},{"key":"5510_CR25","doi-asserted-by":"publisher","unstructured":"Nadakuditi S. Role of telemedicine in improving access to specialized care in rural health systems and its future in health care delivery. J Health Stat Rep. 2022;1\u20133. https:\/\/doi.org\/10.47363\/JHSR\/2022(1)118.","DOI":"10.47363\/JHSR\/2022(1)118"},{"key":"5510_CR26","doi-asserted-by":"publisher","unstructured":"Nativi-Nicolau J, Sarswat N, Fajardo J, Finkel M, Abdulsattar Y, Casta\u00f1o A, Klein L, Haddad-Angulo A. Best practices in specialized amyloidosis centers in the united states: A survey of Cardiologists, Nurses, patients, and patient advocates. Clin Med Insights Cardiol. 2021;15. https:\/\/doi.org\/10.1177\/11795468211015230.","DOI":"10.1177\/11795468211015230"},{"key":"5510_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.20517\/mtod.2024.15","volume":"4","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. Diabetes mellitus and heart disease. Metab Target Organ Damage. 2024;4:18. https:\/\/doi.org\/10.20517\/mtod.2024.15.","journal-title":"Metab Target Organ Damage"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05510-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:29:49Z","timestamp":1771928989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05510-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5510"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05510-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7864719\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used de-identified, publicly available mortality data from the CDC WONDER database and did not involve direct human participants or animal subjects. Institutional review board approval and informed consent were therefore not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The study used de-identified, publicly available data and did not include individual-level identifiable information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}